First drug discovered and designed with generative AI enters Phase II trials, with first patients dosed
Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that it has completed the first dose in patients in the Phase...
















